# A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

> **NCT06327295** · PHASE2 · RECRUITING · sponsor: **AmtixBio Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** ATB1651-102- Cohort 1
- **DRUG:** ATB1651-102- Cohort 2
- **DRUG:** ATB1651-102- Cohort 3
- **DRUG:** ATB1651-102- Cohort 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06327295
- **Lead sponsor:** AmtixBio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06327295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06327295, "A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06327295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*